PODDInsulet Corporation
$148.66
$0.45
(0.30%)
Closed $147.69
$0.97
(0.66%)
After Hours
EarningsAug 6
Mkt Cap$10.26B
Vol942,276.00
Fundamentals
61
Bullish Sentiment
How do you feel about PODD?
Abbott's CGM Growth Story Stays Intact Despite Q1 Moderation
ABT's CGM sales growth slows in Q1, but management sees a return to double-digit gains as Libre expands with new products and AI tools.
Zacks
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
Insulet Reveals New Data Supporting Breakthrough Omnipod 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing...
Business Wire
Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?
Key PointsDexCom is a leading innovator in the continuous glucose monitoring market with a global footprint across 52 countries...
Nasdaq News: Markets
Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced its planned activities during the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5 8, 2026 in New...
Business Wire
Tandem Diabetes Valuation: Is 1.1x Sales a Buy?
TNDM trades near 1.1x forward sales as it shifts to pharmacy pay-as-you-go and expands Europe, with a $21 target tied to 1.3x sales.
Zacks
Insulet Announces U.S. Rollout of Enhanced Omnipod 5 Algorithm and Expands Compatibility with Abbotts FreeStyle Libre 3 Plus Sensor
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced the U.S. rollout of new algorithm enhancements for the Omnipod 5 Automated Insulin Delivery (AID) System. The updates follow FDA...
Business Wire
TNDM Stock: What to Know About Tandem's 2026 Reset
Tandem Diabetes' Q1 beat, fatter margins and positive cash flow fuel its 2026 reset as it shifts more U.S. pump starts to pay-as-you-go pharmacy.
Zacks
Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
<
1
2
...
>
Advertisement|Remove ads.
Latest PODD News
ViewAbbott's CGM Growth Story Stays Intact Despite Q1 Moderation
Zacks
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
Zacks
Insulet Reveals New Data Supporting Breakthrough Omnipod 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care
Business Wire
Advertisement|Remove ads.